BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10762600)

  • 21. [The tumor suppressor gene p53 (part one). Structure, function and mechanisms of inactivation].
    Martin A
    Ann Pathol; 1995; 15(3):178-83. PubMed ID: 7639853
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of dihydropyrimidinase-related protein 4 as a novel target of the p53 tumor suppressor in the apoptotic response to DNA damage.
    Kimura J; Kudoh T; Miki Y; Yoshida K
    Int J Cancer; 2011 Apr; 128(7):1524-31. PubMed ID: 20499313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transcriptional targets of p53 in apoptosis control.
    Yu J; Zhang L
    Biochem Biophys Res Commun; 2005 Jun; 331(3):851-8. PubMed ID: 15865941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
    Müller P; Nenutil R; Vojtĕsek B
    Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The p53 tumour suppressor protein.
    Hickman ES; Helin K
    Biotechnol Genet Eng Rev; 2000; 17():179-211. PubMed ID: 11255666
    [No Abstract]   [Full Text] [Related]  

  • 26. [Cell cycle regulation after exposure to ionizing radiation].
    Teyssier F; Bay JO; Dionet C; Verrelle P
    Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
    Baptiste N; Friedlander P; Chen X; Prives C
    Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53--an acrobat in tumorigenesis.
    Moll UM; Schramm LM
    Crit Rev Oral Biol Med; 1998; 9(1):23-37. PubMed ID: 9488246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
    Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
    Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis.
    Hussain SP; Harris CC
    J Nippon Med Sch; 2006 Apr; 73(2):54-64. PubMed ID: 16641528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.
    Chen X; Ko LJ; Jayaraman L; Prives C
    Genes Dev; 1996 Oct; 10(19):2438-51. PubMed ID: 8843196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53: the attractive tumor suppressor in the cancer research field.
    Ozaki T; Nakagawara A
    J Biomed Biotechnol; 2011; 2011():603925. PubMed ID: 21188172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
    King TC; Estalilla OC; Safran H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redox modulation of p53: mechanisms and functional significance.
    Kim DH; Kundu JK; Surh YJ
    Mol Carcinog; 2011 Apr; 50(4):222-34. PubMed ID: 21465572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The subcellular distribution of the p53 tumour suppressor, and organismal ageing.
    Wesierska-Gadek J; Schmid G
    Cell Mol Biol Lett; 2005; 10(3):439-53. PubMed ID: 16217555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural biology of the tumor suppressor p53 and cancer-associated mutants.
    Joerger AC; Fersht AR
    Adv Cancer Res; 2007; 97():1-23. PubMed ID: 17419939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 and cell-cycle control: a finger in every pie.
    North S; Hainaut P
    Pathol Biol (Paris); 2000 Apr; 48(3):255-70. PubMed ID: 10858958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.
    Brachmann RK; Yu K; Eby Y; Pavletich NP; Boeke JD
    EMBO J; 1998 Apr; 17(7):1847-59. PubMed ID: 9524109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 and p21waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas.
    Divan A; Lawry J; Dunsmore IR; Parsons MA; Royds JA
    Cancer Res; 2001 Apr; 61(7):3157-63. PubMed ID: 11306502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.
    Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D
    Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.